LT4850B - Junginiai ir kompozicijos, skirti neuronų augimo stimuliavimui ir pailginimui - Google Patents

Junginiai ir kompozicijos, skirti neuronų augimo stimuliavimui ir pailginimui Download PDF

Info

Publication number: LT4850B
Authority: LT; Lithuania
Prior art keywords: alkyl; compound; group; compounds; aryl
Prior art date: 1998-07-17

Application number

LT2001012A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT2001012A (en

Inventor

Susumu Katoh

Hiroshi Kawakami

Hiroki Tada

Angelica Maria Linton

Jesus Ernest Villafranca

John Howard Tatlock

Vincent Kalish

Original Assignee

Agouron Pharmaceuticals,Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-17

Filing date

2001-02-15

Publication date

2001-10-25

2001-02-15 Application filed by Agouron Pharmaceuticals,Inc. filed Critical Agouron Pharmaceuticals,Inc.

2001-07-25 Publication of LT2001012A publication Critical patent/LT2001012A/xx

2001-10-25 Publication of LT4850B publication Critical patent/LT4850B/lt

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 216
239000000203 mixture Substances 0.000 title abstract description 39
230000004936 stimulating effect Effects 0.000 title description 4
230000007514 neuronal growth Effects 0.000 title description 2
-1 benzyloxy, phenoxy, amino Chemical group 0.000 claims description 72
125000000217 alkyl group Chemical group 0.000 claims description 60
125000003118 aryl group Chemical group 0.000 claims description 42
125000001424 substituent group Chemical group 0.000 claims description 32
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 25
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 24
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
125000003342 alkenyl group Chemical group 0.000 claims description 23
125000003545 alkoxy group Chemical group 0.000 claims description 23
229910052760 oxygen Inorganic materials 0.000 claims description 23
125000000753 cycloalkyl group Chemical group 0.000 claims description 21
239000001257 hydrogen Substances 0.000 claims description 20
229910052739 hydrogen Inorganic materials 0.000 claims description 20
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 17
239000001301 oxygen Substances 0.000 claims description 17
229920006395 saturated elastomer Polymers 0.000 claims description 17
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 15
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
229910052757 nitrogen Inorganic materials 0.000 claims description 12
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 11
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
229910052799 carbon Inorganic materials 0.000 claims description 10
125000004432 carbon atom Chemical group C* 0.000 claims description 10
125000000623 heterocyclic group Chemical group 0.000 claims description 10
229910052736 halogen Inorganic materials 0.000 claims description 9
125000005842 heteroatom Chemical group 0.000 claims description 9
125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
229910052717 sulfur Inorganic materials 0.000 claims description 8
125000003302 alkenyloxy group Chemical group 0.000 claims description 7
125000004104 aryloxy group Chemical group 0.000 claims description 7
150000002367 halogens Chemical class 0.000 claims description 7
125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 6
125000004093 cyano group Chemical group *C#N 0.000 claims description 6
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
125000005805 dimethoxy phenyl group Chemical group 0.000 claims description 5
239000011593 sulfur Substances 0.000 claims description 5
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 claims description 4
125000004429 atom Chemical group 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
125000003710 aryl alkyl group Chemical group 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 1
125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
125000002541 furyl group Chemical group 0.000 claims 1
125000001041 indolyl group Chemical group 0.000 claims 1
125000001624 naphthyl group Chemical group 0.000 claims 1
125000004076 pyridyl group Chemical group 0.000 claims 1
125000001544 thienyl group Chemical group 0.000 claims 1
108010027179 Tacrolimus Binding Proteins Proteins 0.000 abstract description 36
102000018679 Tacrolimus Binding Proteins Human genes 0.000 abstract description 36
101710103508 FK506-binding protein Proteins 0.000 abstract description 26
101710104425 FK506-binding protein 2 Proteins 0.000 abstract description 26
101710104423 FK506-binding protein 3 Proteins 0.000 abstract description 26
101710104333 FK506-binding protein 4 Proteins 0.000 abstract description 26
101710104342 FK506-binding protein 5 Proteins 0.000 abstract description 26
101710149710 FKBP-type 16 kDa peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract description 26
101710121306 FKBP-type 22 kDa peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract description 26
101710180800 FKBP-type peptidyl-prolyl cis-trans isomerase FkpA Proteins 0.000 abstract description 26
101710104030 Long-type peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract description 26
101710114693 Outer membrane protein MIP Proteins 0.000 abstract description 26
101710116692 Peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract description 26
101710111764 Peptidyl-prolyl cis-trans isomerase FKBP10 Proteins 0.000 abstract description 26
101710111749 Peptidyl-prolyl cis-trans isomerase FKBP11 Proteins 0.000 abstract description 26
101710111747 Peptidyl-prolyl cis-trans isomerase FKBP12 Proteins 0.000 abstract description 26
101710111757 Peptidyl-prolyl cis-trans isomerase FKBP14 Proteins 0.000 abstract description 26
101710111682 Peptidyl-prolyl cis-trans isomerase FKBP1A Proteins 0.000 abstract description 26
101710111689 Peptidyl-prolyl cis-trans isomerase FKBP1B Proteins 0.000 abstract description 26
101710147154 Peptidyl-prolyl cis-trans isomerase FKBP2 Proteins 0.000 abstract description 26
101710147149 Peptidyl-prolyl cis-trans isomerase FKBP3 Proteins 0.000 abstract description 26
101710147152 Peptidyl-prolyl cis-trans isomerase FKBP4 Proteins 0.000 abstract description 26
102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 abstract description 26
101710147150 Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 abstract description 26
101710147138 Peptidyl-prolyl cis-trans isomerase FKBP7 Proteins 0.000 abstract description 26
101710147137 Peptidyl-prolyl cis-trans isomerase FKBP8 Proteins 0.000 abstract description 26
101710147136 Peptidyl-prolyl cis-trans isomerase FKBP9 Proteins 0.000 abstract description 26
101710174853 Peptidyl-prolyl cis-trans isomerase Mip Proteins 0.000 abstract description 26
101710200991 Peptidyl-prolyl cis-trans isomerase, rhodopsin-specific isozyme Proteins 0.000 abstract description 26
101710092145 Peptidyl-prolyl cis-trans isomerase-like 1 Proteins 0.000 abstract description 26
101710092146 Peptidyl-prolyl cis-trans isomerase-like 2 Proteins 0.000 abstract description 26
101710092148 Peptidyl-prolyl cis-trans isomerase-like 3 Proteins 0.000 abstract description 26
101710092149 Peptidyl-prolyl cis-trans isomerase-like 4 Proteins 0.000 abstract description 26
101710113444 Probable parvulin-type peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract description 26
101710090737 Probable peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract description 26
101710133309 Putative peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract description 26
101710124237 Short-type peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract description 26
238000000034 method Methods 0.000 abstract description 20
239000008194 pharmaceutical composition Substances 0.000 abstract description 20
230000002401 inhibitory effect Effects 0.000 abstract description 19
230000000694 effects Effects 0.000 abstract description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
201000010099 disease Diseases 0.000 abstract description 8
210000002569 neuron Anatomy 0.000 abstract description 8
208000014674 injury Diseases 0.000 abstract description 6
238000011069 regeneration method Methods 0.000 abstract description 6
210000005036 nerve Anatomy 0.000 abstract description 5
230000008929 regeneration Effects 0.000 abstract description 5
230000008733 trauma Effects 0.000 abstract description 4
102000009658 Peptidylprolyl Isomerase Human genes 0.000 abstract description 3
108010020062 Peptidylprolyl Isomerase Proteins 0.000 abstract description 3
210000002241 neurite Anatomy 0.000 abstract description 2
125000003367 polycyclic group Chemical group 0.000 abstract description 2
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
230000003190 augmentative effect Effects 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
230000003961 neuronal insult Effects 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 115
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 79
235000019439 ethyl acetate Nutrition 0.000 description 57
239000000243 solution Substances 0.000 description 48
239000011541 reaction mixture Substances 0.000 description 33
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 29
230000007423 decrease Effects 0.000 description 26
108010025020 Nerve Growth Factor Proteins 0.000 description 25
238000003818 flash chromatography Methods 0.000 description 21
239000002904 solvent Substances 0.000 description 21
239000011734 sodium Substances 0.000 description 19
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
239000003795 chemical substances by application Substances 0.000 description 18
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
239000003921 oil Substances 0.000 description 16
235000019198 oils Nutrition 0.000 description 16
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
238000000746 purification Methods 0.000 description 15
150000003839 salts Chemical class 0.000 description 15
102000007072 Nerve Growth Factors Human genes 0.000 description 14
108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 14
239000003900 neurotrophic factor Substances 0.000 description 14
238000003786 synthesis reaction Methods 0.000 description 14
239000012044 organic layer Substances 0.000 description 13
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 12
230000027455 binding Effects 0.000 description 12
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 12
125000006239 protecting group Chemical group 0.000 description 12
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
102000015336 Nerve Growth Factor Human genes 0.000 description 11
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
239000002552 dosage form Substances 0.000 description 11
229940053128 nerve growth factor Drugs 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
DOPQDFLISIANJT-UHFFFAOYSA-N 2-methoxy-4-oxo-3-(2-phenylmethoxyethyl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylic acid Chemical compound COC1C(N2C(O)=O)CCCC2C(=O)N1CCOCC1=CC=CC=C1 DOPQDFLISIANJT-UHFFFAOYSA-N 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
239000003153 chemical reaction reagent Substances 0.000 description 10
239000007787 solid Substances 0.000 description 10
239000000725 suspension Substances 0.000 description 10
238000012360 testing method Methods 0.000 description 10
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 9
239000006184 cosolvent Substances 0.000 description 9
150000002431 hydrogen Chemical class 0.000 description 9
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
239000000126 substance Substances 0.000 description 9
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 9
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 8
102000004631 Calcineurin Human genes 0.000 description 8
108010042955 Calcineurin Proteins 0.000 description 8
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
210000003050 axon Anatomy 0.000 description 8
239000003112 inhibitor Substances 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
238000003556 assay Methods 0.000 description 7
230000002255 enzymatic effect Effects 0.000 description 7
238000001704 evaporation Methods 0.000 description 7
230000008020 evaporation Effects 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
238000011282 treatment Methods 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
239000000969 carrier Substances 0.000 description 6
229920000159 gelatin Polymers 0.000 description 6
235000019322 gelatine Nutrition 0.000 description 6
230000012010 growth Effects 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000000463 material Substances 0.000 description 6
230000000508 neurotrophic effect Effects 0.000 description 6
KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 6
239000000047 product Substances 0.000 description 6
239000000758 substrate Substances 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
230000003376 axonal effect Effects 0.000 description 5
239000002775 capsule Substances 0.000 description 5
150000001721 carbon Chemical group 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
229940125904 compound 1 Drugs 0.000 description 5
229940125782 compound 2 Drugs 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
229940014259 gelatin Drugs 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
230000002209 hydrophobic effect Effects 0.000 description 5
230000001506 immunosuppresive effect Effects 0.000 description 5
239000008101 lactose Substances 0.000 description 5
239000002207 metabolite Substances 0.000 description 5
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
229910052763 palladium Inorganic materials 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
239000001267 polyvinylpyrrolidone Substances 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
239000000651 prodrug Substances 0.000 description 5
229940002612 prodrug Drugs 0.000 description 5
239000002002 slurry Substances 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
239000003826 tablet Substances 0.000 description 5
238000004448 titration Methods 0.000 description 5
YIFZKKNLDDIGOW-UHFFFAOYSA-N 1-[4-oxo-3-(2-phenylmethoxyethyl)-3,9-diazabicyclo[3.3.1]nonan-9-yl]-2-(3,4,5-trimethoxyphenyl)ethane-1,2-dione Chemical compound COC1=C(OC)C(OC)=CC(C(=O)C(=O)N2C3CCCC2CN(CCOCC=2C=CC=CC=2)C3=O)=C1 YIFZKKNLDDIGOW-UHFFFAOYSA-N 0.000 description 4
BZPHEWDJGQSUAP-UHFFFAOYSA-N 1-o-benzyl 2-o-methyl 6-methoxypiperidine-1,2-dicarboxylate Chemical compound COC1CCCC(C(=O)OC)N1C(=O)OCC1=CC=CC=C1 BZPHEWDJGQSUAP-UHFFFAOYSA-N 0.000 description 4
BLPGDSCPUUKKAW-UHFFFAOYSA-N 2,4-dioxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid Chemical compound C1CCC2C(=O)OC(=O)C1N2C(=O)O BLPGDSCPUUKKAW-UHFFFAOYSA-N 0.000 description 4
NLDLANZATQCWAG-UHFFFAOYSA-N 2-hydroxy-3-[2-(2-methoxyphenyl)ethyl]-4-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylic acid Chemical compound COC1=CC=CC=C1CCN1C(=O)C(N2C(O)=O)CCCC2C1O NLDLANZATQCWAG-UHFFFAOYSA-N 0.000 description 4
NQHIUDRFTLPUHP-UHFFFAOYSA-N 3-(2-phenylmethoxyethyl)-3,9-diazabicyclo[3.3.1]nonan-4-one Chemical compound O=C1C(N2)CCCC2CN1CCOCC1=CC=CC=C1 NQHIUDRFTLPUHP-UHFFFAOYSA-N 0.000 description 4
HUPLGGMFMJHZMQ-UHFFFAOYSA-N 3-[2-(2-methoxyphenyl)ethyl]-2,4-dioxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylic acid Chemical compound COC1=CC=CC=C1CCN1C(=O)C(N2C(O)=O)CCCC2C1=O HUPLGGMFMJHZMQ-UHFFFAOYSA-N 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
102000004230 Neurotrophin 3 Human genes 0.000 description 4
108090000742 Neurotrophin 3 Proteins 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
208000006011 Stroke Diseases 0.000 description 4
239000012267 brine Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
239000011575 calcium Substances 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000002156 mixing Methods 0.000 description 4
230000001537 neural effect Effects 0.000 description 4
229940032018 neurotrophin 3 Drugs 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
239000003039 volatile agent Substances 0.000 description 4
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
DXFXWEYKQRMGDX-UHFFFAOYSA-N 1-[5-oxo-4-(2-phenylethyl)-4,10-diazabicyclo[4.3.1]decan-10-yl]-2-(3,4,5-trimethoxyphenyl)ethane-1,2-dione Chemical compound COC1=C(OC)C(OC)=CC(C(=O)C(=O)N2C3CCCC2CCN(CCC=2C=CC=CC=2)C3=O)=C1 DXFXWEYKQRMGDX-UHFFFAOYSA-N 0.000 description 3
VGJSDWHAZRTSAC-UHFFFAOYSA-N 2-(2,2-dimethoxyethyl)-6-(2-phenylethylcarbamoyl)piperidine-1-carboxylic acid Chemical compound OC(=O)N1C(CC(OC)OC)CCCC1C(=O)NCCC1=CC=CC=C1 VGJSDWHAZRTSAC-UHFFFAOYSA-N 0.000 description 3
IMIXMWNUAWEFDR-UHFFFAOYSA-N 2-(2,2-dimethoxyethyl)-6-(4-phenylbutylcarbamoyl)piperidine-1-carboxylic acid Chemical compound OC(=O)N1C(CC(OC)OC)CCCC1C(=O)NCCCCC1=CC=CC=C1 IMIXMWNUAWEFDR-UHFFFAOYSA-N 0.000 description 3
DYQMPAHZHOTPDM-UHFFFAOYSA-N 2-(3,4,5-trimethoxy-6-oxocyclohexa-2,4-dien-1-yl)acetic acid Chemical compound COC1=CC(CC(O)=O)C(=O)C(OC)=C1OC DYQMPAHZHOTPDM-UHFFFAOYSA-N 0.000 description 3
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 3
ACUCQJYDYSIZLX-UHFFFAOYSA-N 5-oxo-4-(4-phenylbutyl)-4,10-diazabicyclo[4.3.1]dec-2-ene-10-carboxylic acid Chemical compound OC(=O)N1C(C=C2)CCCC1C(=O)N2CCCCC1=CC=CC=C1 ACUCQJYDYSIZLX-UHFFFAOYSA-N 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108090000317 Chymotrypsin Proteins 0.000 description 3
229940126657 Compound 17 Drugs 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
102000000521 Immunophilins Human genes 0.000 description 3
108010016648 Immunophilins Proteins 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
208000018737 Parkinson disease Diseases 0.000 description 3
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 3
150000008064 anhydrides Chemical class 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
230000028600 axonogenesis Effects 0.000 description 3
239000002585 base Substances 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
229960002376 chymotrypsin Drugs 0.000 description 3
229940126543 compound 14 Drugs 0.000 description 3
229940125758 compound 15 Drugs 0.000 description 3
229940126214 compound 3 Drugs 0.000 description 3
229940125898 compound 5 Drugs 0.000 description 3
230000027326 copulation Effects 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000010685 fatty oil Substances 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
229960001031 glucose Drugs 0.000 description 3
150000002430 hydrocarbons Chemical group 0.000 description 3
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
239000003018 immunosuppressive agent Substances 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
239000010410 layer Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
208000028591 pheochromocytoma Diseases 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 3
230000009467 reduction Effects 0.000 description 3
108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
LWPQLFXXVSKRJE-UHFFFAOYSA-N tert-butyl 5-oxo-4-(2-phenylethyl)-4,10-diazabicyclo[4.3.1]decane-10-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(CC2)CCCC1C(=O)N2CCC1=CC=CC=C1 LWPQLFXXVSKRJE-UHFFFAOYSA-N 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
BSVHTRRLCAVQCZ-JDEXMCKMSA-N (2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrro Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 BSVHTRRLCAVQCZ-JDEXMCKMSA-N 0.000 description 2
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
DLRJEALIFQWVPD-UHFFFAOYSA-N 2,4-dioxo-3-(2-phenylmethoxyethyl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylic acid Chemical compound OC(=O)N1C(C2=O)CCCC1C(=O)N2CCOCC1=CC=CC=C1 DLRJEALIFQWVPD-UHFFFAOYSA-N 0.000 description 2
CXNUWQKVEZXZPI-UHFFFAOYSA-N 2,4-dioxo-3-(4-phenylbutyl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylic acid Chemical compound OC(=O)N1C(C2=O)CCCC1C(=O)N2CCCCC1=CC=CC=C1 CXNUWQKVEZXZPI-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
VOOLHWPXPFEYAH-UHFFFAOYSA-N 3,3-dimethyl-2-oxopentanoic acid Chemical compound CCC(C)(C)C(=O)C(O)=O VOOLHWPXPFEYAH-UHFFFAOYSA-N 0.000 description 2
COYLRCKGOQEXOF-UHFFFAOYSA-N 3-(4-phenylbutyl)-3,9-diazabicyclo[3.3.1]nonane-2,4-dione Chemical compound O=C1C(N2)CCCC2C(=O)N1CCCCC1=CC=CC=C1 COYLRCKGOQEXOF-UHFFFAOYSA-N 0.000 description 2
AGNFWIZBEATIAK-UHFFFAOYSA-N 4-phenylbutylamine Chemical compound NCCCCC1=CC=CC=C1 AGNFWIZBEATIAK-UHFFFAOYSA-N 0.000 description 2
UGJDLGZNYPPWCI-UHFFFAOYSA-N 6-(2,2-dimethoxyethyl)-1-phenylmethoxycarbonylpiperidine-2-carboxylic acid Chemical compound COC(OC)CC1CCCC(C(O)=O)N1C(=O)OCC1=CC=CC=C1 UGJDLGZNYPPWCI-UHFFFAOYSA-N 0.000 description 2
LKONCASRJFJFCV-UHFFFAOYSA-N 6-(2,3-dihydroxypropyl)piperidine-1,2-dicarboxylic acid Chemical compound OCC(O)CC1CCCC(C(O)=O)N1C(O)=O LKONCASRJFJFCV-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
208000006373 Bell palsy Diseases 0.000 description 2
102000003922 Calcium Channels Human genes 0.000 description 2
108090000312 Calcium Channels Proteins 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
206010028372 Muscular weakness Diseases 0.000 description 2
208000028389 Nerve injury Diseases 0.000 description 2
108090000099 Neurotrophin-4 Proteins 0.000 description 2
102100033857 Neurotrophin-4 Human genes 0.000 description 2
108010077495 Peptide oostatic hormone Proteins 0.000 description 2
208000010886 Peripheral nerve injury Diseases 0.000 description 2
BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
208000036826 VIIth nerve paralysis Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
150000001649 bromium compounds Chemical class 0.000 description 2
239000000872 buffer Substances 0.000 description 2
108010044481 calcineurin phosphatase Proteins 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000008298 dragée Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000000227 grinding Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
150000004694 iodide salts Chemical class 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000002502 liposome Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
201000006938 muscular dystrophy Diseases 0.000 description 2
230000036473 myasthenia Effects 0.000 description 2
230000008764 nerve damage Effects 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
208000004296 neuralgia Diseases 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
210000004498 neuroglial cell Anatomy 0.000 description 2
230000009689 neuronal regeneration Effects 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229940068886 polyethylene glycol 300 Drugs 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000011084 recovery Methods 0.000 description 2
125000006413 ring segment Chemical group 0.000 description 2
230000007017 scission Effects 0.000 description 2
210000000413 sensory ganglia Anatomy 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229960002930 sirolimus Drugs 0.000 description 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000007901 soft capsule Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
208000020431 spinal cord injury Diseases 0.000 description 2
210000003594 spinal ganglia Anatomy 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
125000000547 substituted alkyl group Chemical group 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
OBSLWIKITOYASJ-YDEIVXIUSA-N (3r,4r,5s,6r)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical class CN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OBSLWIKITOYASJ-YDEIVXIUSA-N 0.000 description 1
125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
VOSHMGARUITELT-UHFFFAOYSA-N 1-o-benzyl 2-o-methyl 6-(2,2-dimethoxyethyl)piperidine-1,2-dicarboxylate Chemical compound COC(OC)CC1CCCC(C(=O)OC)N1C(=O)OCC1=CC=CC=C1 VOSHMGARUITELT-UHFFFAOYSA-N 0.000 description 1
VXPYVIRHDQMPQA-UHFFFAOYSA-N 1-o-benzyl 2-o-methyl 6-(2-oxoethyl)piperidine-1,2-dicarboxylate Chemical compound COC(=O)C1CCCC(CC=O)N1C(=O)OCC1=CC=CC=C1 VXPYVIRHDQMPQA-UHFFFAOYSA-N 0.000 description 1
YXDQKTBJURVLSM-UHFFFAOYSA-N 1-phenylmethoxycarbonylpiperidine-2,6-dicarboxylic acid Chemical compound OC(=O)C1CCCC(C(O)=O)N1C(=O)OCC1=CC=CC=C1 YXDQKTBJURVLSM-UHFFFAOYSA-N 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
WSWPCNMLEVZGSM-UHFFFAOYSA-N 2-(2-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC=C1CCN WSWPCNMLEVZGSM-UHFFFAOYSA-N 0.000 description 1
CABMTIJINOIHOD-UHFFFAOYSA-N 2-[4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]quinoline-3-carboxylic acid Chemical compound N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O CABMTIJINOIHOD-UHFFFAOYSA-N 0.000 description 1
KSWOGAYUDSFADX-RPKMEZRRSA-N 2-amino-9-[(2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-2-methyl-3-sulfanyloxolan-2-yl]-1H-purin-6-one Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1S KSWOGAYUDSFADX-RPKMEZRRSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
XJGVVOAKITWCAB-UHFFFAOYSA-N 2-phenylmethoxyethanamine Chemical compound NCCOCC1=CC=CC=C1 XJGVVOAKITWCAB-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
LKDMKWNDBAVNQZ-WJNSRDFLSA-N 4-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(2s)-1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-WJNSRDFLSA-N 0.000 description 1
RVWGRTSNDNPMBG-UHFFFAOYSA-N 4-oxo-3-(2-phenylmethoxyethyl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylic acid Chemical compound OC(=O)N1C(C2)CCCC1C(=O)N2CCOCC1=CC=CC=C1 RVWGRTSNDNPMBG-UHFFFAOYSA-N 0.000 description 1
KAROJVLUHIUHES-UHFFFAOYSA-N 6-(2,2-dimethoxyethyl)piperidine-1,2-dicarboxylic acid Chemical compound COC(OC)CC1CCCC(C(O)=O)N1C(O)=O KAROJVLUHIUHES-UHFFFAOYSA-N 0.000 description 1
KLZPSKDLWRCZHZ-UHFFFAOYSA-N 6-(2-oxoethyl)piperidine-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCCC(CC=O)N1C(O)=O KLZPSKDLWRCZHZ-UHFFFAOYSA-N 0.000 description 1
PHIXHCAJIUYQGY-UHFFFAOYSA-N 6-methoxycarbonyl-1-phenylmethoxycarbonylpiperidine-2-carboxylic acid Chemical compound COC(=O)C1CCCC(C(O)=O)N1C(=O)OCC1=CC=CC=C1 PHIXHCAJIUYQGY-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HXBATGBSCSYHHE-UHFFFAOYSA-N 9-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]-3-(4-phenylbutyl)-3,9-diazabicyclo[3.3.1]nonane-2,4-dione Chemical compound COC1=C(OC)C(OC)=CC(C(=O)C(=O)N2C3CCCC2C(N(CCCCC=2C=CC=CC=2)C3=O)=O)=C1 HXBATGBSCSYHHE-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
ZQLDTXULFJRWJF-UHFFFAOYSA-N C(=O)=O.ClC(C(F)(F)F)(F)Cl.ClC(F)(Cl)Cl.ClC(F)(F)Cl Chemical compound C(=O)=O.ClC(C(F)(F)F)(F)Cl.ClC(F)(Cl)Cl.ClC(F)(F)Cl ZQLDTXULFJRWJF-UHFFFAOYSA-N 0.000 description 1
MHNODLOODLXSPW-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)N1C(CCCC1OC)C(=O)O Chemical compound C(C1=CC=CC=C1)OC(=O)N1C(CCCC1OC)C(=O)O MHNODLOODLXSPW-UHFFFAOYSA-N 0.000 description 1
101000975407 Caenorhabditis elegans Inositol 1,4,5-trisphosphate receptor itr-1 Proteins 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
WJJMNDUMQPNECX-UHFFFAOYSA-N Dipicolinic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
101000975393 Drosophila melanogaster Inositol 1,4,5-trisphosphate receptor Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
102000024452 GDNF Human genes 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 1
108010032354 Inositol 1,4,5-Trisphosphate Receptors Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
206010029333 Neurosis Diseases 0.000 description 1
102000003683 Neurotrophin-4 Human genes 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
108010001441 Phosphopeptides Proteins 0.000 description 1
102000009097 Phosphorylases Human genes 0.000 description 1
108010073135 Phosphorylases Proteins 0.000 description 1
229920002642 Polysorbate 65 Polymers 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
239000005700 Putrescine Substances 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
229910010165 TiCu Inorganic materials 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
229940124532 absorption promoter Drugs 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000012445 acidic reagent Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
229940040563 agaric acid Drugs 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
239000011609 ammonium molybdate Substances 0.000 description 1
235000018660 ammonium molybdate Nutrition 0.000 description 1
229940010552 ammonium molybdate Drugs 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
YITKLWGJAVPDSF-UHFFFAOYSA-N benzyl 2-(2,2-dimethoxyethyl)-6-(2-phenylethylcarbamoyl)piperidine-1-carboxylate Chemical compound COC(OC)CC1CCCC(C(=O)NCCC=2C=CC=CC=2)N1C(=O)OCC1=CC=CC=C1 YITKLWGJAVPDSF-UHFFFAOYSA-N 0.000 description 1
XZJZONVADOBCAK-UHFFFAOYSA-N benzyl 4-oxo-3-(2-phenylmethoxyethyl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate Chemical compound O=C1N(CCOCC=2C=CC=CC=2)CC2CCCC1N2C(=O)OCC1=CC=CC=C1 XZJZONVADOBCAK-UHFFFAOYSA-N 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
238000005282 brightening Methods 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
101710185079 cAMP-dependent protein kinase regulatory subunit Proteins 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000000500 calorimetric titration Methods 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Natural products O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
230000003915 cell function Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
239000012069 chiral reagent Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
230000001886 ciliary effect Effects 0.000 description 1
238000007697 cis-trans-isomerization reaction Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
229940125877 compound 31 Drugs 0.000 description 1
239000012084 conversion product Substances 0.000 description 1
238000007334 copolymerization reaction Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013058 crude material Substances 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
RQYGKZGKXDOUEO-LFZNUXCKSA-N dihydro-fk-506 Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CCC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 RQYGKZGKXDOUEO-LFZNUXCKSA-N 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
AASUFOVSZUIILF-UHFFFAOYSA-N diphenylmethanone;sodium Chemical compound [Na].C=1C=CC=CC=1C(=O)C1=CC=CC=C1 AASUFOVSZUIILF-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
210000000609 ganglia Anatomy 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
125000000592 heterocycloalkyl group Chemical group 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
125000006038 hexenyl group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
231100000171 higher toxicity Toxicity 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
230000028993 immune response Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
CFNHVUGPXZUTRR-UHFFFAOYSA-N n'-propylethane-1,2-diamine Chemical group CCCNCCN CFNHVUGPXZUTRR-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
230000007971 neurological deficit Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000007557 neuronal destruction Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
208000015238 neurotic disease Diseases 0.000 description 1
229940097998 neurotrophin 4 Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000035699 permeability Effects 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940117803 phenethylamine Drugs 0.000 description 1
DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
239000000049 pigment Substances 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
QGTZWKPSXZYWOQ-UHFFFAOYSA-N piperidine-1,2,6-tricarboxylic acid Chemical compound OC(=O)C1CCCC(C(O)=O)N1C(O)=O QGTZWKPSXZYWOQ-UHFFFAOYSA-N 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229940099511 polysorbate 65 Drugs 0.000 description 1
230000017363 positive regulation of growth Effects 0.000 description 1
CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
229910000343 potassium bisulfate Inorganic materials 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000029983 protein stabilization Effects 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000010948 rhodium Substances 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
229940091258 selenium supplement Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000000779 smoke Substances 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000005945 translocation Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
HYWCXWRMUZYRPH-UHFFFAOYSA-N trimethyl(prop-2-enyl)silane Chemical compound C[Si](C)(C)CC=C HYWCXWRMUZYRPH-UHFFFAOYSA-N 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)

LT2001012A 1998-07-17 2001-02-15 Junginiai ir kompozicijos, skirti neuronų augimo stimuliavimui ir pailginimui LT4850B (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9329998P	1998-07-17	1998-07-17
US13288499P	1999-05-06	1999-05-06

Publications (2)

Publication Number	Publication Date
LT2001012A LT2001012A (en)	2001-07-25
LT4850B true LT4850B (lt)	2001-10-25

Family

ID=26787372

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT2001012A LT4850B (lt)	1998-07-17	2001-02-15	Junginiai ir kompozicijos, skirti neuronų augimo stimuliavimui ir pailginimui

Country Status (35)

Country	Link
US (1)	US6630472B1 (et)
EP (1)	EP1098897B1 (et)
JP (1)	JP2002520413A (et)
KR (1)	KR20010071920A (et)
CN (1)	CN1318067A (et)
AP (1)	AP2001002052A0 (et)
AT (1)	ATE268772T1 (et)
AU (1)	AU756912B2 (et)
BG (1)	BG105268A (et)
BR (1)	BR9912423A (et)
CA (1)	CA2337377A1 (et)
DE (1)	DE69917907T2 (et)
DK (1)	DK1098897T3 (et)
EA (1)	EA200100149A1 (et)
EE (1)	EE200100032A (et)
ES (1)	ES2226409T3 (et)
GE (1)	GEP20043368B (et)
HR (1)	HRP20010118A2 (et)
HU (1)	HUP0200637A3 (et)
ID (1)	ID27428A (et)
IL (1)	IL140676A0 (et)
IS (1)	IS5805A (et)
LT (1)	LT4850B (et)
LV (1)	LV12665B (et)
NO (1)	NO20010191L (et)
NZ (1)	NZ509211A (et)
OA (1)	OA11581A (et)
PL (1)	PL345598A1 (et)
PT (1)	PT1098897E (et)
SI (1)	SI20638A (et)
SK (1)	SK462001A3 (et)
TR (1)	TR200100122T2 (et)
WO (1)	WO2000004020A1 (et)
YU (1)	YU2901A (et)
ZA (1)	ZA200100320B (et)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6818643B1 (en) *	1999-12-08	2004-11-16	Bristol-Myers Squibb Company	Neurotrophic bicyclic diamides
JP2004532854A (ja) *	2001-05-10	2004-10-28	アグロンファ−マシュ−テイカルズインコ−ポレイテッド	複素２環式ｆｋｂｐリガンド
EP2899192A1 (en) *	2014-01-24	2015-07-29	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders
EP3097103B1 (en) *	2014-01-24	2017-11-15	Max-Planck-Gesellschaft zur Förderung der Wissenschaften	Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5192773A (en)	1990-07-02	1993-03-09	Vertex Pharmaceuticals, Inc.	Immunosuppressive compounds
WO1996040140A1 (en)	1995-06-07	1996-12-19	Guilford Pharmaceuticals Inc.	Inhibitors of rotamase enzyme activity
WO1996041609A2 (en)	1995-06-08	1996-12-27	Vertex Pharmaceuticals Incorporated	Methods and compositions for stimulating neurite growth
US5612350A (en)	1993-11-30	1997-03-18	Abbott Laboratories	Macrocyclic immunomodulators with novel cyclohexyl ring replacements
US5614547A (en)	1995-06-07	1997-03-25	Guilford Pharmaceuticals Inc.	Small molecule inhibitors of rotamase enzyme
US5721256A (en)	1997-02-12	1998-02-24	Gpi Nil Holdings, Inc.	Method of using neurotrophic sulfonamide compounds

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4894366A (en)	1984-12-03	1990-01-16	Fujisawa Pharmaceutical Company, Ltd.	Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5196352A (en)	1989-01-19	1993-03-23	Merck & Co., Inc.	New FK-506 cytosolic binding protein
US5109112A (en)	1989-01-19	1992-04-28	Merck & Co., Inc.	FK-506 cytosolic binding protein
US5187166A (en) *	1990-07-31	1993-02-16	Nisshin Flour Milling Co., Ltd.	Azabicyclo derivatives and their use as antiemetics
US5256656A (en) *	1990-07-31	1993-10-26	Nisshin Flour Milling Co., Ltd.	Azabicyclo derivatives
CA2068062A1 (en)	1991-05-07	1992-11-08	Stephen A. Parent	Yeast mutants
US5362629A (en)	1991-08-05	1994-11-08	President And Fellows Of Harvard College	Detection of immunosuppressants
US5344831A (en) *	1992-01-31	1994-09-06	Nisshin Flour Milling Co., Ltd.	Diazabicyclo derivatives
DE4219973A1 (de)	1992-06-19	1993-12-23	Basf Ag	N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
US5318895A (en)	1992-10-05	1994-06-07	Merck & Co., Inc.	Aspergillus niger mutants
US5798355A (en)	1995-06-07	1998-08-25	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity
JP3235913B2 (ja) *	1993-07-30	2001-12-04	エーザイ株式会社	アミノ安息香酸誘導体
DE4341402A1 (de)	1993-12-04	1995-06-08	Basf Ag	N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
US5457182A (en)	1994-02-15	1995-10-10	Merck & Co., Inc.	FK-506 cytosolic binding protein, FKBP12.6
US5622866A (en)	1994-06-23	1997-04-22	Merck & Co., Inc.	Expression cassettes useful in construction of integrative and replicative expression vectors for Streptomyces
US5859031A (en) *	1995-06-07	1999-01-12	Gpi Nil Holdings, Inc.	Small molecule inhibitors of rotamase enzyme activity
US5801197A (en)	1995-10-31	1998-09-01	Gpi Nil Holdings, Inc.	Rotamase enzyme activity inhibitors
US5801187A (en)	1996-09-25	1998-09-01	Gpi-Nil Holdings, Inc.	Heterocyclic esters and amides
US5786378A (en)	1996-09-25	1998-07-28	Gpi Nil Holdings, Inc.	Heterocyclic thioesters
US5811434A (en)	1996-11-13	1998-09-22	Vertex Pharmacueticals Incorporated	Methods and compositions for stimulating neurite growth
US5780484A (en)	1996-11-13	1998-07-14	Vertex Pharmaceuticals Incorporated	Methods for stimulating neurite growth with piperidine compounds
US5840736A (en)	1996-11-13	1998-11-24	Vertex Pharmaceuticals Incorporated	Methods and compositions for stimulating neurite growth
AR010744A1 (es)	1996-12-09	2000-07-12	Guildford Pharmaceuticals Inc	Inhibidores polipropilos de ciclofilina
US5874449A (en)	1996-12-31	1999-02-23	Gpi Nil Holdings, Inc.	N-linked sulfonamides of heterocyclic thioesters
US5935989A (en)	1996-12-31	1999-08-10	Gpi Nil Holdings Inc.	N-linked ureas and carbamates of heterocyclic thioesters
ZA98825B (en)	1997-02-27	1998-10-19	Guilford Pharm Inc	Method of using neurotrophic carbamates and ureas
US5846979A (en)	1997-02-28	1998-12-08	Gpi Nil Holdings, Inc.	N-oxides of heterocyclic esters, amides, thioesters, and ketones

1999
- 1999-07-15 CN CN99810848A patent/CN1318067A/zh active Pending
- 1999-07-15 EE EEP200100032A patent/EE200100032A/et unknown
- 1999-07-15 JP JP2000560126A patent/JP2002520413A/ja not_active Withdrawn
- 1999-07-15 EP EP99934043A patent/EP1098897B1/en not_active Expired - Lifetime
- 1999-07-15 OA OA1200100015A patent/OA11581A/en unknown
- 1999-07-15 PT PT99934043T patent/PT1098897E/pt unknown
- 1999-07-15 EA EA200100149A patent/EA200100149A1/ru unknown
- 1999-07-15 AU AU49963/99A patent/AU756912B2/en not_active Ceased
- 1999-07-15 HR HR20010118A patent/HRP20010118A2/hr not_active Application Discontinuation
- 1999-07-15 GE GE4273A patent/GEP20043368B/en unknown
- 1999-07-15 CA CA002337377A patent/CA2337377A1/en not_active Abandoned
- 1999-07-15 AT AT99934043T patent/ATE268772T1/de not_active IP Right Cessation
- 1999-07-15 HU HU0200637A patent/HUP0200637A3/hu unknown
- 1999-07-15 SI SI9920067A patent/SI20638A/sl not_active IP Right Cessation
- 1999-07-15 ES ES99934043T patent/ES2226409T3/es not_active Expired - Lifetime
- 1999-07-15 AP APAP/P/2001/002052A patent/AP2001002052A0/en unknown
- 1999-07-15 NZ NZ509211A patent/NZ509211A/xx unknown
- 1999-07-15 KR KR1020017000654A patent/KR20010071920A/ko not_active Ceased
- 1999-07-15 SK SK46-2001A patent/SK462001A3/sk unknown
- 1999-07-15 IL IL14067699A patent/IL140676A0/xx unknown
- 1999-07-15 PL PL99345598A patent/PL345598A1/xx not_active Application Discontinuation
- 1999-07-15 BR BR9912423-8A patent/BR9912423A/pt not_active Application Discontinuation
- 1999-07-15 TR TR2001/00122T patent/TR200100122T2/xx unknown
- 1999-07-15 WO PCT/US1999/015965 patent/WO2000004020A1/en not_active Ceased
- 1999-07-15 DK DK99934043T patent/DK1098897T3/da active
- 1999-07-15 YU YU2901A patent/YU2901A/sh unknown
- 1999-07-15 ID IDW20010130A patent/ID27428A/id unknown
- 1999-07-15 DE DE69917907T patent/DE69917907T2/de not_active Expired - Fee Related
- 1999-07-16 US US09/356,240 patent/US6630472B1/en not_active Expired - Fee Related
2001
- 2001-01-11 ZA ZA200100320A patent/ZA200100320B/en unknown
- 2001-01-12 IS IS5805A patent/IS5805A/is unknown
- 2001-01-12 NO NO20010191A patent/NO20010191L/no not_active Application Discontinuation
- 2001-02-15 LT LT2001012A patent/LT4850B/lt not_active IP Right Cessation
- 2001-02-16 BG BG105268A patent/BG105268A/xx unknown
- 2001-03-13 LV LV010023A patent/LV12665B/lv unknown

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5192773A (en)	1990-07-02	1993-03-09	Vertex Pharmaceuticals, Inc.	Immunosuppressive compounds
US5330993A (en)	1990-07-02	1994-07-19	Vertex Pharmaceuticals, Inc.	Immunosuppressive compounds
US5516797A (en)	1990-07-02	1996-05-14	Vertex Pharmaceuticals, Incorporated	Immunosuppressive compounds
US5622970A (en)	1990-07-02	1997-04-22	Vertex Pharmaceuticals, Incorporated	Immunosuppressive compounds
US5665774A (en)	1990-07-02	1997-09-09	Armistead; David M.	Immunosuppressive compounds
US5612350A (en)	1993-11-30	1997-03-18	Abbott Laboratories	Macrocyclic immunomodulators with novel cyclohexyl ring replacements
WO1996040140A1 (en)	1995-06-07	1996-12-19	Guilford Pharmaceuticals Inc.	Inhibitors of rotamase enzyme activity
US5614547A (en)	1995-06-07	1997-03-25	Guilford Pharmaceuticals Inc.	Small molecule inhibitors of rotamase enzyme
US5696135A (en)	1995-06-07	1997-12-09	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
WO1996041609A2 (en)	1995-06-08	1996-12-27	Vertex Pharmaceuticals Incorporated	Methods and compositions for stimulating neurite growth
US5721256A (en)	1997-02-12	1998-02-24	Gpi Nil Holdings, Inc.	Method of using neurotrophic sulfonamide compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GUNTER FISCHER ET AL.: "Conformational specificity of chymotrypsin toward proline-containing substrates", BIOCHIMICA ET BIOPHYSICA ACTA (BBA), 1984, pages 87 - 97
GUNTER FISCHER ET AL.: "Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins", BIOCHIM. BIOPHYS. ACTA, 1984, pages 476 - 478
J. J. SIEKIERKA ET AL.: "A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin", NATURE, 1989, pages 755 - 757, XP001018902, DOI: doi:10.1038/341755a0
MATTHEW W. HARDING ET AL.: "A receptor for the immuno-suppressant FK506 is a cisâ€"trans peptidyl-prolyl isomerase", NATURE, 1989, pages 758 - 760
W. ERNEST LYONS ET AL.: "Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia", PNAS, 1994, pages 3191 - 3195

Also Published As

Publication number	Publication date
HUP0200637A2 (en)	2002-08-28
PT1098897E (pt)	2004-10-29
BR9912423A (pt)	2001-06-05
AP2001002052A0 (en)	2001-03-31
EP1098897B1 (en)	2004-06-09
DE69917907D1 (de)	2004-07-15
GEP20043368B (en)	2004-04-13
HUP0200637A3 (en)	2003-05-28
NZ509211A (en)	2002-10-25
IL140676A0 (en)	2002-02-10
TR200100122T2 (tr)	2001-08-21
JP2002520413A (ja)	2002-07-09
NO20010191D0 (no)	2001-01-12
OA11581A (en)	2004-07-23
CA2337377A1 (en)	2000-01-27
KR20010071920A (ko)	2001-07-31
HRP20010118A2 (en)	2002-02-28
EP1098897A1 (en)	2001-05-16
SK462001A3 (en)	2002-02-05
WO2000004020A1 (en)	2000-01-27
DE69917907T2 (de)	2005-06-30
LV12665B (lv)	2001-11-20
PL345598A1 (en)	2001-12-17
EE200100032A (et)	2002-06-17
LV12665A (en)	2001-05-20
ZA200100320B (en)	2002-07-11
NO20010191L (no)	2001-03-16
ID27428A (id)	2001-04-05
BG105268A (en)	2001-11-30
DK1098897T3 (da)	2004-10-18
AU756912B2 (en)	2003-01-23
EA200100149A1 (ru)	2001-08-27
ES2226409T3 (es)	2005-03-16
CN1318067A (zh)	2001-10-17
LT2001012A (en)	2001-07-25
SI20638A (sl)	2002-02-28
IS5805A (is)	2001-01-12
YU2901A (sh)	2004-05-12
US6630472B1 (en)	2003-10-07
ATE268772T1 (de)	2004-06-15
AU4996399A (en)	2000-02-07

Publication	Publication Date	Title
CN113631557B (zh)	2024-03-15	Jak激酶抑制剂及其制备方法和在医药领域的应用
RU2329265C2 (ru)	2008-07-20	ТЕТРАГИДРО-4Н-ПИРИДО[1,2-а]ПИРИМИДИНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ВИЧ-ИНТЕГРАЗЫ
EA012666B1 (ru)	2009-12-30	Оптическое разделение (1-бензил-4-метилпиперидин-3-ил)метиламина и его применение для получения производных пирроло 2,3-пиримидина в качестве ингибиторов протеинкиназы
EP1664050B1 (en)	2015-12-09	Neuroprotective bicyclic compounds and pharmaceutical compositions containing them
CN103415520A (zh)	2013-11-27	吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用
US11203597B2 (en)	2021-12-21	Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing
KR20130009763A (ko)	2013-01-23	야누스 키나아제 억제제로서의 사이클로부탄 및 메틸사이클로부탄 유도체
US10294230B2 (en)	2019-05-21	3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
JP7009504B2 (ja)	2022-01-25	ヤヌスキナーゼ阻害剤としての新規アミノイミダゾピリジン誘導体及びそれらの医薬としての使用
AU2017257211A1 (en)	2018-10-11	Polymorphic form of N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
CN112898269A (zh)	2021-06-04	化合物的结晶形式
EP0460116B1 (en)	1997-08-27	9-substituted-8-unsubstituted-9-deazaguanines
JP2004534002A (ja)	2004-11-11	化合物
LT4850B (lt)	2001-10-25	Junginiai ir kompozicijos, skirti neuronų augimo stimuliavimui ir pailginimui
CZ2001105A3 (cs)	2001-07-11	Sloučeniny, prostředky a způsoby stimulace neuronálního růstu a prodloužení
MXPA01000441A (en)	2001-12-04	Compounds, compositions, and methods for stimulating neuronal growth and elongation
HK40045075A (en)	2021-10-15	Crystalline forms of a compound
HK40058222A (en)	2022-04-22	A crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing
HK1262749B (en)	2023-04-21	Crystalline form of a compound, preparation, and uses thereof
HK40013317A (en)	2020-08-07	Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
HK1262749A1 (en)	2020-01-17	Crystalline form of a compound, preparation, and uses thereof

Legal Events

Date	Code	Title	Description
2006-03-27	MM9A	Lapsed patents	Effective date: 20050715